©TheCanadian Journal ofUrology™: International Supplement, April 2014
104
Emerging therapies in castration resistant prostate cancer
Conclusion
Building on decades of research, the past few years
have yielded a near exponential increase in treatment
modalities for patientswithmetastatic prostate cancer.
Individually, these improvements in overall survival
may appearmodest, however, nearly all of them have
a distinct mechanism of action and the possibility of
synergistic effects have yet to be established. Going
forward,thepromiseofadurableimpactonthemortality
frommetastatic prostate cancer will likely stem from
further elucidation ofmolecular pathways involved in
prostatecancer,aswellasdefiningtheoptimalsequence
of treatment forpatientswithmetastaticprostatecancer.
Disclosure
Drs.GregoryR. Thoreson, BishoyA.GayedandPaul
H. Chunghavenopotential conflict of interest.
Dr. Ganesh Raj has served on Speaker/Advisory
boards of Bayer, Janssen, Medivation, Astellas and
Merck.Hehasseveralpatentapplicationsonpotential
therapeutics (not discussed in this article) inprostate
cancer.Healsoreceivesresearch funding from Janssen
andC-diagnosticsCorp.
References
1. CancerFacts&Figures2014.Atlanta:AmericanCancerSociety.
2014.
2. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and
estramustinecomparedwithmitoxantroneandprednisone for
advancedrefractoryprostatecancer.
NEngl JMed
2004:351(15):
1513-1520.
3. Tannock IF,deWitR,BerryWRetal.Docetaxelplusprednisone
ormitoxantroneplusprednisone foradvancedprostatecancer.
NEngl JMed
2004;351(15):1502-1512.
4. Logothetis CJ. Treatment of castrate-resistant prostate cancer.
JUrol
2013;190(2):439-440.
5. HugginsC,HodgesCV.Studiesonprostaticcancer. I.Theeffect
of castration, of estrogen and androgen injection on serum
phosphatases inmetastaticcarcinomaof theprostate.
CACancer
J Clin
1972;22(4):232-240.
6. SeidenfeldJ,SamsonDJ,HasselbladVetal.Single-therapyandrogen
suppression inmenwithadvancedprostate cancer: a systematic
reviewandmeta-analysis.
Ann InternMed
2000;132(7):566-577.
7. Kolvenbag GJ, Nash A. Bicalutamide dosages used in the
treatment of prostate cancer.
Prostate
1999;39(1):47-53.
8. FerroMA,GillattD,SymesMO,SmithPJ.High-dose intravenous
estrogen therapy in advanced prostatic carcinoma. Use of
serum prostate-specific antigen to monitor response.
Urology
1989;34(3):134-138.
9. TangenCM, Faulkner JR,CrawfordEDet al.Ten-year survival
inpatientswithmetastaticprostate cancer.
ClinProstateCancer
2003;2(1):41-45.
10.HussainM,TangenCM,HiganoCetal.Absoluteprostate-specific
antigenvalueafterandrogendeprivation isastrong independent
predictor of survival in newmetastatic prostate cancer: data
from Southwest Oncology Group Trial 9346 (INT-0162).
JClinOncol
2006;24(24):3984-3990.
11.Hussain M, Goldman B, Tangen C et al. Prostate-specific
antigen progression predicts overall survival in patientswith
metastatic prostate cancer: data from Southwest Oncology
GroupTrials9346 (IntergroupStudy0162)and9916.
JClinOncol
2009;27(15):2450-2556.
12.TsaoCK, GalskyMD, SmallAC, Yee T, OhWK. Targeting the
androgenreceptorsignallingaxis incastration-resistantprostate
cancer (CRPC).
BJU Int
2012;110(11):1580-1588.
13.Chen CD, Welsbie DS, Tran C et al. Molecular determinants
of resistance to antiandrogen therapy.
Nat Med
2004;10(1):
33-39.
14.TitusMA,SchellMJ,LihFB,TomerKB,Mohler JL.Testosterone
and dihydrotestosterone tissue levels in recurrent prostate
cancer.
ClinCancerRes
2005;11(13):4653-4657.
15.MontgomeryRB,Mostaghel EA,VessellaR et al.Maintenance
of intratumoral androgens in metastatic prostate cancer:
amechanism for castration-resistant tumorgrowth.
CancerRes
2008;68(11):4447-4454.
16.TranC,OukS,CleggNJetal.Developmentofasecond-generation
antiandrogen for treatment of advanced prostate cancer.
Science
2009;324(5928):787-790.
17.Scher HI, Beer TM, Higano CS et al. Antitumour activity of
MDV3100 in castration-resistant prostate cancer: a phase 1-2
study.
Lancet
2010;375(9724):1437-1446.
18.ScherHI Fizazi K, Saad F, TaplinME et al. Increased survival
with enzalutamide in prostate cancer after chemotherapy.
NEngl JMed
2012;367(13):1187-1197.
19.Astellas Pharma US Inc., I., Highlights of Prescribing
Information. 08/12.
ENZ-WPI.PDF.
20.BeerTMetal.Enzalutamidedecreasesriskofdeathanddelays
progression in phase III trial of menwithmetastatic prostate
cancer. Presentation at ASCO 2014 Genitourinary Cancers
Symposium.
21.Clegg NJ, Wongvipat J, Joseph JD et al. ARN-509: a novel
antiandrogenforprostatecancertreatment.
CancerRes
2012;72(6):
1494-1503.
22.Barrie SE, Haynes BP, Potter GA et al. Biochemistry and
pharmacokinetics of potent non-steroidal cytochrome
P450(17alpha) inhibitors.
JSteroidBiochemMolBiol
1997;60(5-6):
347-351.
23.de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and
increased survival inmetastatic prostate cancer.
NEngl JMed
2011;364(21):1995-2005.
24.RyanCJ, SmithMR, deBono JSet al.Abiraterone inmetastatic
prostate cancerwithout previous chemotherapy.
NEngl JMed
2013;368(2):138-148.
25.GeorgeDJ, CornPG,MichaelsonMD et al. Safety and activity
of the investigationalagentorteronel (ortl)withoutprednisone
in men with nonmetastatic castration-resistant prostate
cancer (nmCRPC) and rising prostate-specific antigen (PSA):
Updated results of a phase II study.
J ClinOncol
2012;(suppl;
abstr 4549).
26.Agus DB, StadlerWM, ShevrinDH et al. Safety, efficacy, and
pharmacodynamics of the investigational agent TAK-700 in
metastaticcastration-resistantprostatecancer(mCRPC):Updated
data from a phase I/II study.
J ClinOncol
29:2011;(Suppl 15);
Abstract: 4531.
27.TakedaAnnouncesUnblindingofPhase3StudyofOrteronel in
PatientswithMetastatic, Castration-Resistant ProstateCancer
ThatProgressedPost-ChemotherapyBasedonInterimAnalysis.
,
Accessed July 26, 2013.
